Get the Stockscreener App
14.62
0.41%
0.13
Benitec Biopharma Inc stock is traded at $14.62, with a volume of 25,710.
It is up +0.41% in the last 24 hours and up +50.00% over the past month.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
See More
Previous Close:
$14.49
Open:
$14.89
24h Volume:
25,710
Relative Volume:
0.55
Market Cap:
$346.85M
Revenue:
$59,000
Net Income/Loss:
$-21.81M
P/E Ratio:
-1.3349
EPS:
-10.9518
Net Cash Flow:
$-18.07M
1W Performance:
+12.01%
1M Performance:
+50.00%
6M Performance:
+78.53%
1Y Performance:
+180.35%
1-Day Range:
$14.14
$15.01
1-Week Range:
$11.99
$15.01
52-Week Range:
$4.75
$15.01
Benitec Biopharma Inc Stock (BNTC) Company Profile
Name
Benitec Biopharma Inc
Sector
Industry
Phone
(510) 780-0819
Address
3940 TRUST WAY, HAYWARD, CA
Compare BNTC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BNTC
Benitec Biopharma Inc
|
14.72 | 346.85M | 59,000 | -21.81M | -18.07M | -10.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.80 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
682.17 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.04 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.41 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
252.35 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Benitec Biopharma Inc Stock (BNTC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-24 | Initiated | H.C. Wainwright | Buy |
| Dec-13-24 | Initiated | Robert W. Baird | Outperform |
| Oct-16-24 | Initiated | Oppenheimer | Outperform |
| Sep-12-24 | Initiated | Guggenheim | Buy |
| Jul-22-24 | Initiated | Leerink Partners | Outperform |
| Jun-13-24 | Initiated | Piper Sandler | Overweight |
| Oct-05-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Apr-20-20 | Initiated | Ladenburg Thalmann | Buy |
| Feb-26-16 | Downgrade | Maxim Group | Buy → Hold |
| Dec-31-15 | Reiterated | Maxim Group | Buy |
| Sep-16-15 | Reiterated | Maxim Group | Buy |
View All
Benitec Biopharma Inc Stock (BNTC) Latest News
BenitecAnother Biopharma Rocket - Barchart
Benitec Biopharma (NASDAQ:BNTC) Shares Cross Above 50-Day Moving Average – Here’s Why - Defense World
Benitec BiopharmaGetting To The Roots Of Oculopharyngeal Muscular Dystrophy - RTTNews
Benitec Biopharma stock soars to 52-week high of $13.32 By Investing.com - Investing.com Australia
Benitec Biopharma stock soars to 52-week high of $13.32 - Investing.com India
Benitec Biopharma (NASDAQ:BNTC) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
How to Take Advantage of moves in (BNTC) - Stock Traders Daily
Antisense & RNAi Therapeutics Market to Set Remarkable Growth - openPR
Benitec Biopharma to Participate in Upcoming Conferences in March - GlobeNewswire
Reviewing NexImmune (NASDAQ:NEXI) & Benitec Biopharma (NASDAQ:BNTC) - Defense World
Benitec Biopharma's SWOT analysis: gene therapy stock shows promise amid trials By Investing.com - Investing.com South Africa
Benitec Biopharma’s SWOT analysis: gene therapy stock shows promise amid trials - Investing.com India
Benitec Biopharma's SWOT analysis: gene therapy stock shows promise amid trials - Investing.com
Wall Street Analysts Predict a 127.26% Upside in Benitec Biopharma (BNTC): Here's What You Should Know - MSN
HC Wainwright Reiterates “Buy” Rating for Benitec Biopharma (NASDAQ:BNTC) - Defense World
(BNTC) Pivots Trading Plans and Risk Controls - Stock Traders Daily
H.C. Wainwright maintains $28 target on Benitec BioPharma stock By Investing.com - Investing.com UK
Benitec Biopharma (BNTC) is on the Move, Here's Why the Trend Could be Sustainable - Yahoo Finance
Citizens JMP maintains Benitec stock with $18 target By Investing.com - Investing.com Australia
Citizens JMP maintains Benitec stock with $18 target - Investing.com India
Benitec Biopharma (NASDAQ:BNTC) Announces Earnings Results, Beats Estimates By $0.19 EPS - MarketBeat
Benitec Biopharma Inc. (NASDAQ:BNTC) Receives Consensus Rating of “Buy” from Analysts - Defense World
Benitec Biopharma Inc. (NASDAQ:BNTC) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Benitec Biopharma (NASDAQ:BNTC) Stock Price Passes Below 50-Day Moving AverageHere's What Happened - MarketBeat
Benitec Biopharma Inc. Announces Q4 2024 Financial Results and Operational Update - Defense World
Benitec Biopharma Announces Acceptance of Late- Breaking - GlobeNewswire
Benitec presents new gene therapy data at MD conference By Investing.com - Investing.com Canada
Benitec presents new gene therapy data at MD conference - Investing.com India
Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update - TradingView
Benitec Biopharma Inc. Announces Late-Breaking Presentation on BB-301 Phase 1b/2a Clinical Study for Oculopharyngeal Muscular Dystrophy at 2025 MDA Conference - Nasdaq
Benitec Biopharma Announces Acceptance of Late- Breaking Oral Abstract for the BB-301 Phase 1b/2a Clinical Study at the Muscular Dystrophy Association Clinical and Scientific Conference - The Manila Times
Benitec Biopharma Inc. (BNTC) reports earnings - Quartz
Benitec Biopharma Announces Acceptance of Late- Breaking Oral Abstract for the BB-301 Phase 1b/2a Clinical Study at the Muscular Dystrophy Association Clinical and Scientific Conference - GlobeNewswire Inc.
Benitec Biopharma Inc. SEC 10-Q Report - TradingView
(BNTC) Investment Analysis - Stock Traders Daily
Benitec Biopharma (BNTC) Expected to Announce Quarterly Earnings on Monday - Defense World
Benitec Biopharma (BNTC) Projected to Post Earnings on Monday - MarketBeat
Institutional investors are Benitec Biopharma Inc.'s (NASDAQ:BNTC) biggest bettors and were rewarded after last week's US$33m market cap gain - Simply Wall St
Benitec Biopharma (NASDAQ:BNTC) Share Price Crosses Above Fifty Day Moving AverageHere's What Happened - MarketBeat
(BNTC) Technical Pivots with Risk Controls - Stock Traders Daily
Franklin Resources Inc. Acquires Significant Stake in Benitec Bi - GuruFocus.com
Benitec Biopharma to Participate in Upcoming Conferences in January and February - GlobeNewswire
BNTCBenitec Biopharma Inc. Latest Stock News & Market Updates - StockTitan
Benitec Biopharma Announces Three Major Conference Presentations for Early 2025 - StockTitan
Guggenheim Initiates Coverage of Benitec Biopharma (BNTC) with Buy Recommendation - MSN
Benitec Biopharma Inc Stock (BNTC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Benitec Biopharma Inc Stock (BNTC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 23 '24 |
Buy |
10.98 |
27,502 |
301,972 |
7,981,725 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 24 '24 |
Buy |
11.25 |
20,018 |
225,202 |
7,999,455 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 03 '24 |
Buy |
9.60 |
42,000 |
403,200 |
7,957,365 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Nov 20 '24 |
Buy |
10.22 |
27,436 |
280,396 |
7,920,175 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Nov 19 '24 |
Buy |
9.73 |
14,000 |
136,220 |
7,895,815 |
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):